Nuvalent (NUVL)
(Delayed Data from NSDQ)
$77.90 USD
-1.22 (-1.54%)
Updated Jul 30, 2024 04:00 PM ET
After-Market: $77.85 -0.05 (-0.06%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
NUVL 77.90 -1.22(-1.54%)
Will NUVL be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for NUVL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NUVL
Why Earnings Season Could Be Great for Nuvalent (NUVL)
Nuvalent (NUVL) Soars 36% on Upbeat Initial NSCLC Study Data
NUVL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Recent Price Trend in Nuvalent, Inc. (NUVL) is Your Friend, Here's Why
Nuvalent, Inc. (NUVL) Is a Great Choice for 'Trend' Investors, Here's Why
Are Medical Stocks Lagging DICE Therapeutics (DICE) This Year?
Other News for NUVL
Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor
Nuvalent initiated with a Not Rated at Goldman Sachs
Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024
Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific Officer
Nuvalent: Making Precise Progress In Its Oncology Pipeline